Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2026The European Research JournalOpen Access

Intrapericardial bleomycin for recurrent pericardial effusion lacks clinical trial data or primary outcome results.

View Full Paper
Ask AI
Bookmark
Share

Population

A patient with a 3-year history of lung cancer on regular chemotherapy, presenting with recurrent malignant…

Design

Case_report

Follow-up

1 month

Key result

No clinical trial data or primary outcome results are reported in this document.

Authors

-S- 5th Uludag Cardiology Summit

Discussion

Loading...

Member takes

Overview

Should not change practice based on one case; leaves open need for prospective trials in malignant pericardial effusion.

Key Points

  • This collection of abstracts aims to showcase recent findings in cardiovascular health, focusing on various cardiac diseases, procedures, and prognostic indicators.
  • Meeting abstract presentations reviewing various cases and studies related to cardiovascular conditions
  • Discussion of diagnostic tools such as TAPSE/PASP ratios
  • Exploration of surgical interventions and acute management strategies in cardiovascular patients
  • Analysis of risk indicators in specific populations, such as those with heart failure or diabetes
  • Prognostic indicators, like TAPSE/PASP and ferritin-CRP ratios, reveal important correlations with patient outcomes.
  • Case reports highlight unique complications and management strategies in cardiac interventions.
  • Emerging studies suggest AI may assist in diagnosing cardiac conditions effectively.

Structured PICO

P
Population
A patient with a 3-year history of lung cancer on regular chemotherapy, presenting with recurrent malignant pericardial effusion and cardiac tamponade.
I
Intervention
Intrapericardial bleomycin (15 mg diluted in 35 cc of normal saline)
O
Outcome
Recurrence of pericardial effusionsurrogate

Intrapericardial bleomycin administration successfully prevented the short-term recurrence of malignant pericardial effusion in a patient with lung cancer.

Cite This Study

- 5th Uludag Cardiology Summit (2025) studied this question. No clinical trial data or primary outcome results are reported in this document.

synapsesocial.com/papers/6997fa5aad1d9b11b34537b4https://doi.org/10.18621/eurj.1650977
View Full Paper
Ask AI
Bookmark
Share